Circulatory system

ONCOTELIC REPORTS Q2 2022 COMPARED TO Q2 2021 FINANCIAL RESULTS

Retrieved on: 
Monday, August 22, 2022
BMJ, Cancer, Sexual dysfunction, DIPG, Survival, Research, Ageing, Safety, Form 10-K, PDE5, Apomorphine, McMahon, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, Oxigen Services, FSD, Disease, Man, AML, Risk, ED, Optimism, Food, Male, KJ, Mohammad Ali Allahdadi, SEC, Hartmut Geerken, JV, HSDD, PD, Company, Manifest and latent functions and dysfunctions, Female, Communication, Circulatory system, G&A, Orthostatic syncope, Sertraline, Fluoxetine, Hypotension, Annual report, Woman, CA4P, Melanoma, Private Securities Litigation Reform Act, Cocaine, Forward-looking statement, Patient, New, Animal, Mobile phone, Pharmaceutical industry, Bremelanotide

Comparing Q2 2022 to Q2 2021, we reported a net profit, before non-controlling interests, of approximately $16.0 million compared to a net loss of approximately $3.6 million, respectively.

Key Points: 
  • Comparing Q2 2022 to Q2 2021, we reported a net profit, before non-controlling interests, of approximately $16.0 million compared to a net loss of approximately $3.6 million, respectively.
  • Comparing our research and development (R&D) expenses between Q2 2022 and Q2 2021, our R&D expenses decreased by approximately $0.8 million for Q2 2022 compared to the Q2 2021, primarily due to personnel and operational expenses related to OT-101 being borne by the JV.
  • Comparing our general and administrative (G&A) expenses between Q2, 2022 and Q2 2021, our G&A expenses decreased by approximately $2.6 million, primarily due to lower stock compensation expense of approximately $2.0 million during Q2 2021 as compared to $25 thousand during Q2 2022, and lower compensation and operational expenses of approximately $0.3 million which was borne by the JV.
  • Comparing our interest expense for Q2 2022 and Q2 2021, our interest expense increased by $0.7 million based on approximately $1.1 million for Q2 2022, primarily in connection with debt raised from convertible notes and the JH Darbie Financing, the November 2021 to March 2022 Financing and May/June 2022 financing as compared to $0.4 million for Q2 2021, in connection with debt raised from convertible notes and JH Darbie during 2021.

Real World Evidence Solution Market Report 2022-2027: Shift from Volume to Value Based Care & Delays in Drug Development and the Subsequent Increase in Development Costs Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, August 19, 2022
Data Management, Health, Technology, Practice Management, COVID-19, General Health, Pharmaceutical, Value, Data set, Circulatory system, Business Growth Fund, Growth, USD, Diagnosis, Determining the number of clusters in a data set, Real, Use, Acquisition, Research report, Strategic management, Decision-making, CAGR, Customer support, Component, Market share analysis, Neurology, Retail, Oncology

This research report categorizes the Real World Evidence Solution to forecast the revenues and analyze the trends in each of the following sub-markets:

Key Points: 
  • This research report categorizes the Real World Evidence Solution to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Component, the market was studied across Data Set and Services.
  • The Data Set is further studied across Claims Data, Clinical Settings Data, Patient-Powered Data, and Pharmacy Data.
  • Based on Therapeutic Area, the market was studied across Cardiovascular, Immunology, Infectious Diseases, Neurology, and Oncology.
  • Based on End-User, the market was studied across Biopharmaceutical Company, Clinical & Life Sciences Organization, and Diagnostics or Medical Device Company.

Global Small-Molecule APIs Market Report 2022: Rising Volume of Patients Suffering from Cancer, Cardiovascular, and Infectious Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022
Other Science, Science, Molecule, Gaps, News, Weakness, Synthetic, Value, Business Growth Fund, Research report, Decision-making, Collaborative partnership, CAGR, Investment, API, Market share analysis, Mergers and acquisitions, Circulatory system, Growth, Contract manufacturer, Infection, Use, Acquisition, Contract, Biology, Application, Diabetes, Strategic management, Global, Customer support, Patient, USD, Pharmaceutical industry, Retail, Oncology, Cancer

Based on Application, the market was studied across Cardiovascular, Diabetes, Immunological Disorders, and Oncology.

Key Points: 
  • Based on Application, the market was studied across Cardiovascular, Diabetes, Immunological Disorders, and Oncology.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.
  • Rising Volume of Patients Suffering from Cancer, Cardiovascular, and Infectious Diseases

Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors

Retrieved on: 
Thursday, August 11, 2022
Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, Oncology, Health, Health Technology, Form 10-Q, Cardiology, Thomas Jefferson University, Laboratory, Forward-looking statement, Circulatory system, Internal medicine, Faculty, Senior, Diagnosis, SEC, Chicago (franchise), Annual report, Merck, Cancer, Health, Patient, Chairperson, Twitter, Barr, MRL, Merck & Co., Vaccine, University, Johns Hopkins, Head, Physician, Investor, Bureau of Oceans and International Environmental and Scientific Affairs, Neurology, HPV, Pharmaceutical industry, Medical device, Security (finance), Immunology, Oncology, Psychiatry

Veracyte, Inc. (Nasdaq: VCYT) today announced the appointment of Eliav Barr, M.D., to its board of directors, effective immediately.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced the appointment of Eliav Barr, M.D., to its board of directors, effective immediately.
  • We are thrilled to welcome Eliav Barr to our board, said Marc Stapley, Veracytes chief executive officer.
  • I am excited to join Veracytes board of directors and help guide the company as it executes on its bold, strategic global vision.
  • Veracyte and the Veracyte logo are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries.

U.S. Small-Molecule APIs Market Research Report 2022: Featuring Key Players GlaxoSmithKline, Novartis, Pfizer & Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 2, 2022
Technology, Software, Molecule, Investment, Biology, Market share analysis, Acquisition, Gaps, State, Value, Decision-making, Use, Weakness, Research, Circulatory system, Strategic management, Contract, Customer support, USD, Contract manufacturer, Application, News, CAGR, Synthetic, Mergers and acquisitions, Collaborative partnership, Diabetes, Growth, Business Growth Fund, API, Pharmaceutical industry, Retail, Oncology

This research report categorizes the Small-Molecule APIs to forecast the revenues and analyze the trends in each of the following sub-markets:

Key Points: 
  • This research report categorizes the Small-Molecule APIs to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Production, the market was studied across Contract Manufacturing and In-house Manufacturing.
  • Based on Application, the market was studied across Cardiovascular, Diabetes, Immunological Disorders, and Oncology.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.

Radcliffe Group Chooses MEI Global to Cultivate Licensing Partnerships

Retrieved on: 
Tuesday, July 26, 2022
Knowledge, Time, AER, Editorial, Industry, USC, Medicine, Circulatory system, Health, Arrhythmia, ICR, ECR, Negotiation, Interventional cardiology, Journal, Business development, Science, Patient, Heart, CFR, Life, VER, Metabolism, LLC, Communication, Publishing, Noise, Medical device, Research

BOURNE END, United Kingdom, July 26, 2022 /PRNewswire-PRWeb/ -- Today Radcliffe Group, which brings the latest and best science, information, and knowledge to cardiovascular clinicians around the world, announced it has selected content distribution consultancy MEI Global, LLC (MEIG) to develop third-party licensing partnerships that will help medical practitioners, researchers, and innovators more easily and efficiently access Radcliffe's unique content collection.

Key Points: 
  • MEIG was founded to help publishers identify, negotiate, and grow their third-party distribution partnerships.
  • Chris Broekhoff, MEIG's president, says, "The landscape for content licensing is constantly changing.
  • About MEI Global, LLC: MEIG provides a suite of services to help publishers monetize their digital assets.
  • About Radcliffe Group : We bring medical knowledge to life and put great communication at the heart of better healthcare.

Bayer’s KERENDIA® (finerenone) Receives New Recommendations From American Diabetes Association for Improving Cardiovascular Outcomes and Managing Patients With Chronic Kidney Disease Associated With Type 2 Diabetes

Retrieved on: 
Tuesday, June 28, 2022
Health, Diabetes, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Kidney failure, ARB, Progression, Patient, Finerenone, T2D, Section 11 of the Canadian Charter of Rights and Freedoms, Phase, ADA, Type 2 diabetes, Heart failure, Moderate, RAS, Serum, Incidence, Hospital, Kidney disease, Disease, C1-inhibitor, Circulatory system, Kidney, FACC, Heart, Population, Hyperkalemia, Hypotension, ACE, Cardiovascular disease, Myocardial infarction, Chronic kidney disease, Risk management, Trial of the century, CKD, Risk, Bayer, Diabetes, Potassium, Hyponatremia, Pharmacology, EGFR, Failure, NYHA, CV, Glomerular filtration rate, Acei, Chemistry (relationship), Adult, SOC, Health care, Albuminuria, Mortality, CYP3A4, University, Standard of care, Time-invariant system, Program, Diabetic retinopathy, Pharmaceutical industry, Medical device

At Bayer, we are committed to continuing our long history of researching and providing treatments to fight cardiovascular and kidney diseases.

Key Points: 
  • At Bayer, we are committed to continuing our long history of researching and providing treatments to fight cardiovascular and kidney diseases.
  • Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly.
  • Do not initiate KERENDIA if serum potassium is >5.0 mEq/L4
    Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly.
  • Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging.

United States Podiatry Services Market Report 2022-2027: Cardiovascular Diseases, Diabetes, and Musculoskeletal Diseases - Cumulative Impact of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 27, 2022
Health, Other Health, Circulatory system, Acquisition, Decision-making, USD, Treatment, Musculoskeletal disorder, Strategic management, Market share analysis, Value, Mergers and acquisitions, Business Growth Fund, COVID-19, Customer support, Growth, Human musculoskeletal system, Collaborative partnership, Cardiovascular disease, Investment, CAGR, Diabetes, Weakness, Use, News, Compound annual growth rate, State, Gaps, Consumer, Retail, Application, Service

The "Podiatry Services Market Research Report by Treatment Condition (Cardiovascular diseases, Diabetes, and Musculoskeletal diseases), Service, Application, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Podiatry Services Market Research Report by Treatment Condition (Cardiovascular diseases, Diabetes, and Musculoskeletal diseases), Service, Application, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
  • The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.
  • It provides the idea of its revenue generation into the overall market compared to other vendors in the space.

Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022

Retrieved on: 
Tuesday, June 21, 2022
Hyperkalemia, Chronic kidney disease, Security (finance), FDA, NDA, Metabolic acidosis, NHE3, Regulation of tobacco by the U.S. Food and Drug Administration, Kidney, View, Endpoint security, Tobacco Products Scientific Advisory Committee, Circulatory system, Advisory, U.S. Securities and Exchange Commission, Fosun Pharma, Kyowa Hakko Kirin, New Drug Application, OND, CKD, Diarrhea, Calendar, PAI, Dialysis, Adult, Advisory Committee, Food, Patient, Knight Therapeutics, Multimedia, Therapy, Pharmaceutical industry

The Advisory Committee will discuss the company's New Drug Application (NDA) for XPHOZAH for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

Key Points: 
  • The Advisory Committee will discuss the company's New Drug Application (NDA) for XPHOZAH for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
  • A response from the OND to Ardelyx's appeal is expected within thirty calendar days after the conclusion of the Advisory Committee meeting.
  • XPHOZAH (tenapanor), discovered and developed by Ardelyx, in an investigational first-in-class phosphate absorption inhibitor (PAI).
  • Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs.

AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer

Retrieved on: 
Wednesday, June 1, 2022
Research, Professional Services, Medical Devices, Hospitals, Surgery, Science, Cardiology, Biotechnology, Medical Supplies, Human Resources, FDA, Health, Other Science, Leadership, Circulatory system, LAA, Partnership, Workforce, Â, Human resources, FDA, Growth, Peripheral nervous system, Patient, Twitter, Industry, Culture, Texas Instruments, Management, Atrial fibrillation, Medtronic

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effective today.

Key Points: 
  • AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effective today.
  • We are excited to have Deborah joining us at AtriCure, said Michael Carrel, President and Chief Executive Officer.
  • She brings an incredible amount of industry and human capital expertise as we enter a period of accelerated growth.
  • It is a privilege to be joining AtriCure at such an exciting time in the companys evolution, said Ms. Yount.